NFKB1 and amyotrophic lateral sclerosis: Based on data generated in the ALS field [23], these results suggest that inhibitors of NF-κB activation should be considered for treatment of MCI subtype with episodic memory deficits to prevent the developing AD and that potential therapeutic window would lie before their progression to AD.